

NOTES

MICROBIAL TRANSFORMATION OF
LEUCOMYCIN A₅

KARTAR SINGH and SUMANAS RAKHIT

Ayerst Research Laboratories
Montreal, Quebec, Canada

(Received for publication February 25, 1978)


In an earlier paper from our laboratory¹⁾, antimicrobial activities of various leucomycin (kitasamycin) congeners were compared. In continuation of this work, we tested a large number of microorganisms for their ability to transform leucomycin. Of these, *Actinoplanes missouriensis** (IMRU-824, AY B-866) was found to be the most effective in transforming leucomycin and was used for the present study on transformation of leucomycin A₅.

Leucomycin A₅ conversion was followed by thin-layer chromatography on silica gel, Merck F-254 plates using chloroform-methanol-acetic acid-water (158:22:16:4). The plates were sprayed with 10% H₂SO₄ and heated for 10~15 minutes at 120°C.

The organism was grown in a medium containing 3% glycerol and 3% Special X soy flour (Archer Daniels Midland Co., Minneapolis) for 48~72 hours at 30°C on a rotary shaker; leucomycin was added and incubation continued for an additional 48~72 hours. Alternatively, after 48~72 hours of growth, the cells were collected by centrifugation, washed twice with water and once with 0.02 M phosphate buffer, pH 7.2. They were suspended in the original volume of this buffer; leucomycin was added, and the mixture incubated at 30°C on a rotary shaker. In preliminary experiments, we found that leucomycin-transforming activity of the cells was greatly enhanced if the cells were induced with 10 μg/ml demycarosyl 3-deacetyl leucomycin for 12~24 hours. Using induced cells, 1 mg/ml of leucomycin A₅ was completely transformed in 48~72 hours into one main, more polar product. Demycarosyl 3-deacetyl leucomycin could not be replaced by mycarose, leucomycin complex

or the individual components A₁, A₃ or A₅ as an inducer and was routinely used at 10 μg/ml.

A preparative scale conversion was carried out with leucomycin A₅. Ten 2-liter Erlenmeyer flasks, each containing 400 ml of medium, were inoculated with *A. missouriensis* from agar slants and incubated on a rotary shaker at 30°C for 66 hours. To each flask, 4 mg of demycarosyl 3-deacetyl leucomycin (dissolved in water and filtered through a Millipore 0.45 μm filter) were added. After 24 hours of further incubation, the cells were collected and washed by centrifugation. The washed cells were suspended in 4 liters of 0.02 M phosphate buffer, pH 7.2, and 4 g leucomycin A₅ dissolved in 40 ml of acetone were added. The suspension was distributed into ten 2-liter Erlenmeyer flasks, and the flasks incubated at 30°C on a rotary shaker. After an additional 66 hours of incubation, the reaction mixture was cooled to 5~10°C, adjusted to pH 5.0 with 1 N HCl, and filtered through a bed of Celite. The filtrate was adjusted to pH 8.5 with 1 M Na₂CO₃ and extracted twice with 2 liters of ethylacetate. The combined solvent extracts were washed with 400 ml of water, dried with anhydrous Na₂SO₄

Fig. 1. Transformation of leucomycin A₅

* This organism was obtained from Dr. RUTH GORDON, Institute of Microbiology, Rutgers University, New Brunswick, N.J., U.S.A.

and evaporated to dryness to yield 2.5 g of a product with weak antimicrobial activity (Table 1).

The product was further purified by chromatography over Al_2O_3 (activity III), with 30% ethyl acetate in benzene to afford 1.8 g of pure transformation product, m.p. $68\sim 70^\circ\text{C}$, $\lambda_{\text{max}}^{\text{MeOH}}$ 232 nm ($E_{1\text{cm}}^{1\%}$ 305); NMR δCDCl_3 , CHO, 9.6; OCH_3 , 3.5; $\text{N}(\text{CH}_3)_2$ 2.5; no acyl bands. From the NMR and the UV spectra, it was indicated that this product contained the parent diene chromophore and the aldehydic and mycamino moieties were unchanged. The mass spectrum (MS) of the product showed a weak molecular ion peak characteristic of other macrolides at m/e 701 indicating the loss of the butyryl side chain on the mycarose moiety²³. The appearance of other fragments (Fig. 2) at m/e 585 ($\text{C}_{29}\text{H}_{47}\text{NO}_{11}$) *a*, 319 ($\text{C}_{15}\text{H}_{29}\text{NO}_6$) for *b*, 175 ($\text{C}_8\text{H}_{17}\text{NO}_3$) for *c* and 146 ($\text{C}_7\text{H}_{14}\text{O}_3$) for *d* indicates the transforma-


Table 1. Minimum inhibitory concentration (MIC)* of leucomycin A_5 and its transformation product

Substrate and product	Minimum inhibitory concentration ($\mu\text{g}/\text{ml}$)		
	<i>Staphylococcus pyogenes</i> pen S	<i>Staphylococcus pyogenes</i> pen R	<i>Streptococcus faecalis</i>
Leucomycin A_5	0.8	3.2	0.8
Transformation product of leucomycin A_5	50	100	12.5

* MIC was determined by the usual serial, two-fold, tube dilution method in nutrient broth.

tion product is deacyl leucomycin A_5 (leucomycin V)³. The product was acetylated by acetic anhydride and pyridine at 50°C for 16 hours and purified by chromatography over silica gel (30% acetone in benzene). The identity of the acetylated product with diacetyl leucomycin A_5 pre-

Fig. 2. Plausible fragmentation of deacylated leucomycin A_5



pared similiary from leucomycin A₈²⁾ was established by comparing their NMR and mass spectra, which further confirms the identity of the transformation product.

Acknowledgements

We are grateful to Dr. D. KLUEPFEL for supplying us with various leucomycins, and to Dr. G. SCHILLING and his associates for the spectral analyses. Technical assistance of Mrs. SHEILA SUN and Mrs. ANGELE RICHARD is gratefully acknowledged.

References

- 1) RAKHIT, S. & K. SINGH: Structure activity relationship in sixteen membered macrolide antibiotics. *J. Antibiotics* 27: 221~224, 1974
- 2) INOUE, S.; T. TSURUOKA, T. SHOMURA, S. OMOTO & T. NIIDA: Studies on antibiotic SF-837, a new antibiotic. II. Chemical structure of antibiotic SF-837. *J. Antibiotics* 24: 460~475, 1971
- 3) ŌMURA, S. & A. NAKAGAWA: Chemical and biological studies on 16-membered macrolide antibiotics. *J. Antibiotics* 28: 401~433, 1975